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Gastroesophageal reflux symptoms are common and occur in all ofusfrom time to time. In others,
reflux may be associated with ulcerative esophagitis. The symptoms may be aggravated by large
meals, coffee, smoking andposition. Physiological andpathological reflux can be separatedby the
frequency and duration ofthe exposure ofthe lower esophagus to acid. Pathological reflux results
in symptoms and also esophagitis and ulceration in some patients. Although gastroesophageal
reflux disease (GERD) is considered to resultfrom a disorder ofmotility in the esophagus, gastric
acidandpeptic activityare deemedpivotal to the initiation andcontinuation oftheesophagealdam-
age and the development ofsymptoms. Acid exposure in the esophagus is normally less than 4per-
cent ofthe 24 hours with apHbelow 4. An increase over4percent ofthe time with apH less than
4 is consideredpathological. Hence, antisecretory drugs have become theprinciple approach to the
treatment ofreflux symptoms and esophagitis since they reduce the acidity ofgastricjuice and the
activity ofpepsin. Importantly, they also reduce the volume ofgastricjuice availablefor reflux into
the esophagus.
There is a clear relationship between the degree and duration ofacid suppression and the reliefof
heartburn andhealing ofesophagitis. Pharmacodynamic studies with differentdose regimens ofthe
H2-receptor antagonists and theproton pump inhibitors show a difference in the degree and dura-
tion of the antisecretory effect, and this correlates closely with the results ofclinical trials with
respect to the healing ofesophagitis and the reliefofsymptoms. Proton pump inhibitors achieve
healing rates by weekfour, which are not achieved by H2-receptor antagonists even after 12 weeks
oftreatment. The advantage ofproton pump inhibitors over H -receptor antagonists is due to the
greater degree, longer duration ofeffect and more complete inhibition ofacid secretion that main-
tains intragastric pH above 4for a maximal duration. Although there is no significant difference
betweenprotonpump inhibitors with respect to healing ofesophagitis, symptom reliefoccurs earli-
er with lansoprazole than omeprazole, and this is probably due to the greater oral bioavailability
andfaster onset ofaction oflansoprazole when compared to omeprazole.
INTRODUCTION
Gastroesophageal reflux disease
(GERD)b is considered to be primarily a
motility disorder characterized by abnor-
mally frequent transient relaxations of the
lower esophageal sphincter and loss of
lower esophageal sphincter tone in the
basal state [1]. Both ofthese abnormalities
facilitate reflux of acidic gastric contents
into the lower esophagus. Furthermore,
clearance of the acidic refluxate from the
esophagus is impaired in about 50 percent
ofpatients with GERD [2]. This results in
prolonged exposure of the mucosa of the
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lower esophagus to the damaging effects
of acidic gastric contents. Despite the evi-
dence of dysmotility and the defects in
epithelial resistance in patients with
GERD, gastric acid is considered of cen-
tral importance to the initiation and con-
tinuation of the esophageal damage and
the development of symptoms in patients
with GERD and has been recognized as an
independent pathophysiological factor in
esophagitis [3]. Moreover, the successful
results of antisecretory therapy in patients
with erosive esophagitis support this view
[4,5].
It is well accepted that the suppres-
sion of24-hr gastric acid secretion signifi-
cantly correlates with the healing rates of
duodenal ulcer, gastric ulcer, and erosive
esophagitis [4-7]. Three primary parame-
ters determining the effect ofantisecretory
treatment have been derived from antise-
cretory data. These are the degree of sup-
pression of acidity, the duration of sup-
pression of acidity over 24 hours and the
duration of antisecretory treatment [7-10].
Proton pump inhibitors (PPIs) produce a
greater and longer-lasting degree of sup-
pression of acidity than standard or higher
doses of H2-receptor antagonists (H2RAs)
in 24-hr pH studies. This significantly cor-
relates with the speed ofhealing and relief
of reflux symptoms in patients with grade
II to IV esophagitis as shown in a recent
meta-analysis of randomized controlled
clinical trials consisting of 95 treatment
arms and 7,635 patients with almost two
times more patients healed and symptom-
free per week when treated with PPIs than
with H2RAs [11]. In patients refractory to
standard doses ofH2RAs, poor or no inhi-
bition of gastric acid secretion has been
considered the reason for the treatment
failure [12]. Therefore, suppression of
intragastric acidity over 24 hours plays a
crucial role in the healing of esophagitis
[6]. The longer and the greater the sup-
pression ofgastric acid secretion, the more
esophagitis is healed [6].
GASTRIC ACID SECRETION IN
PATIENTS WITH GERD
Whether gastric acid hypersecretion
exists in patients with GERD is controver-
sial [13-16].The results from the critical
analysis by Hirschowitz show no differ-
ence in basal and maximal gastric acid
secretion between patients with endoscop-
ically defined esophagitis and controls
without esophagitis [13]. However, this
study suffered from several methodologi-
cal problems including possibly different
techniques used for gastric analysis over
the 14-year retrospective period and a
questionable definition of hypersecretion
(greater than 15 meq/hr was used) [17,
18]. The study by Collen et al. shows that
a subgroup of patients were gastric acid
hypersecretors although this result might
be confounded by the inclusion ofpatients
previously on H2-receptor antagonists
studied during the period they might have
acid rebound [14]. In a more recent large
prospective study involving 228 patients,
there was a significant difference in the
mean basal acid output between patients
with GERD (6.5 ± 5.6 meq/hr) and 65 nor-
mal controls (3.0 ± 2.7 meqfhr, p < .0001)
[16]. Although 48.7 percent ofthe patients
had a previous history of H2RA therapy,
only 14.5 percent were taking H2RA dur-
ing the two months prior to the gastric
analysis [16]. Hypersecretion also was
reported in the study of Johansson, who
excluded patients taking H2RA [15]. Thus,
there may be a subset of patients with
GERD who are acid hypersecretors.
RATIONALE OF ACID
SUPPRESSION IN THE
MANAGEMENT OF GERD
Symptoms, mucosal damage and
esophageal acid exposure
There are a number of studies show-
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symptoms and endoscopic esophagitis
correlate significantly with the duration of
gastroesophageal reflux, the degree of
esophageal exposure to gastric acid, and
the pH ofthe refluxate [19-22]. The results
reported by Joelsson et al. have shown that
the severity and frequency ofreflux symp-
toms were associated significantly with
the median duration of esophageal acid
exposure (pH < 4) in 190patients with and
without endoscopic esophagitis when
compared with 50 asymptomatic controls
[19]. In asymptomatic subjects, the medi-
an acid exposure time was 1.1 percent,
while in symptomatic patients without
endoscopic esophagitis, the acid exposure
time was 1.9 percent for patients with
occasional symptoms (grade 1), 3 percent
for those with one to three times occur-
rence of symptoms daily (grade 2) and 3.8
percent for patients with constant symp-
toms (grade 3), respectively. In patients
with endoscopic esophagitis, the corre-
sponding median acidexposure time was 6
percent, 10 percent and 11.2 percent for
patients with symptom grades 1, 2 and 3,
respectively [19]. The longer the duration
ofacid exposure, the more severe were the
symptoms and the esophagitis.
pH4 as a thresholdbetweenpatholog-
icalandphysiological reflux
Animal studies have demonstrated
that esophageal mucosal injury is highly
pH-dependent [21, 23]. Perfusion of the
esophagus over a one-hour period with
hydrochloric acid at varying pH induced
esophagitis only when solutions of pH
below 1.6 were used. The addition of
porcine pepsin to the perfusate increased
the severity of esophagitis and produced
mucosal inflammation with solutions of
between pH 1.3 and 2.3 [23].
Distal intraesophageal pH varies from
5 to 7. A threshold of pH 4 has been sug-
gestedby mostinvestigators as the optimal
pH to discriminate aggressive and non-
aggressive reflux [6, 20, 24] although this
may underestimate the number of reflux
episodes detected by manometry [25].
Why is pH 4 chosen as the pH threshold?
Historical 24-hr pH studies have shown
that heartburn occurred in patients only
when intraesophageal pH monitoring
dropped below 4 [24, 26]. Furthermore,
this pH has proved to be the optimal
threshold in more recent studies. By
applying discriminant analysis and receiv-
er-operating-characteristic analysis,
Schindlbeck et al. evaluated this threshold
comprehensively to define the optimal
threshold for assessing pathological reflux
and found a maximum sensitivity of 93.3
percent and specificity of 92.9 percent by
considering the percentage of time above
pH 4 in both the upright and supine posi-
tions [27]. Although other pH thresholds
may be useful to differentiate between
normal and pathological reflux for the
individual patient, this threshold has
proved to be the optimal and more repro-
ducible [28, 29]. More recently, we have
suggested a new analysis of 24-hr pH
recording as a clinical predictor of
esophageal mucosal damage and endo-
scopic grade of esophagitis by using inte-
grated acidity, expressed as the area under
the curve, to represent total hydrogen
activity (H+) and hence true acid exposure
[30]. A significant correlation has been
shown between area under the curve for
H+ and all grades ofesophagitis [30].
DIFFERENCES BETWEEN ANTISE-
CRETORYTREATMENTS IN
SUPPRESSING GASTRIC ACID
SECRETION
H2RAs
As described above, the frequency of
acid reflux and the exposure time of the
esophagus to acid in patients with GERD
are both increased and correlate with the
severity of the disease. Since most reflux
occurs post-prandially and in the early
evening, treatments to reduce acid reflux
should target both basal acid secretion as184 Huang and Hunt:pH, healing and symptoms in patients with GERD
well as meal-stimulated acid secretion.
Pharmacologically, H2RAs are unable to
overcome the integrated stimulus to acid
secretion produced by a meal [31-34].
Results from a 24-hr pH monitoring study
have shown that neither ranitidine 150 mg
twice daily, nor an increased dose of 300
mg twice daily altered the 22-hour intra-
esophageal pH profile when compared
with pretreatment recordings [35].
Attempts to improve the effect of H2RAs
on reducing evening reflux, by dosing
immediately after the evening meal have
also been unsuccessful in reducing meal-
stimulated acid secretion albeit better than
dosing at bedtime [34, 36]. The percentage
of time with intraesophageal pH above 4
over 24 hours is about 10 hours for this
dose regimen [34, 36]. Increasing doses of
ranitidine from 150 mg three times a day
to 300 mg three times a day significantly
reduced the exposure time of the esopha-
gus to acid from 6.8 percent to 2.5 percent
[37]. This correlates significantly with the
reduction in the frequency and the severity
ofheartburn. Furthermore, there is a corre-
lation between basal acid secretion in
patients with GERD and the dose of rani-
tidine required forhealing esophagitis [16,
38]. However, increasing doses of raniti-
dine above 600 mg/day only increased
modestly the antisecretory effect achieved
with ranitidine 300 mg twice daily [39].
This may be due to the rapid development
of tolerance to H2RAs as seen in normal
volunteers [40] and in patients with reflux
esophagitis [41].
PPIs
PPIs are strong acid suppressing
agents that specifically inhibit the enzyme
of H+K+-ATPase and block the final com-
mon pathway for acid secretion. This is a
prolonged and highly effective inhibition
of both basal and stimulated gastric acid
secretion to all known stimuli including
meals. In comparison with placebo,
omeprazole 10, 20 and 40 mg/day given in
the morning significantly decreases the
frequency of reflux episodes/hr and the
mean percentage of total reflux time over
the 24-hr period from 16.3 percent for the
placebo treatment to 6.3 percent with
omeprazole 10 mg, 0.9 percent with
omeprazole 20 mg and 0.6 percent with
omeprazole 40 mg/day [42].
There are numerous comparative
studies showing that PPIs are superior to
H2RAs in the suppression of gastric acid
secretion in patients with peptic ulcer and
in the reduction of acid reflux in patients
with GERD. In a randomized comparative
study in patients with active gastric ulcer,
lansoprazole 30 mg daily has been shown
to be significantly more effective than
famotidine 20 mg twice daily in maintain-
ing intragastric pH above 3 throughout the
24-hr period (99 percent vs. 68 percent)
with more ulcers healed with lansoprazole
than with famotidine [43]. In another ran-
domized, double-blind study in patients
with grade II to IV esophagitis, Ruth et al.
have shown that omeprazole 20 mg daily
was significantly better than ranitidine 150
mg twice daily in reducing the total reflux
time over the 24-hr period (2.5 percent vs.
6.3 percent, p = .02) and the frequency of
reflux episodes (20 vs. 49, p = .003) [44].
This correlated with a higher healing rate
ofesophagitis seen in patients treated with
omeprazole than with ranitidine [44].
Even when compared with higher doses of
H2RAs (e.g., ranitidine 300 mg or famoti-
dine 40 mg twice daily), omeprazole 20
mg daily offers better results in the reduc-
tion of total reflux time (pH < 4) and the
number of reflux episodes [45, 46], two
important determinants forhealing GERD.
The suppression ofgastric acid secre-
tion has an important impact on the activ-
ity of pepsin as shown in animal studies.
Although the relationship between hyper-
secretion of gastric pepsin and the severi-
ty of GERD is controversial [47, 48], to
inactivate peptic activity by suppressing
gastric acid secretion is a well-accepted
approach for the treatment of acid-related
diseases. In analysis of 24-hr pH studies,
Hirschowitz has shown that the diurnal
intragastric pH during treatment with
cimetidine 1000 mg/day or ranitidine 300
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significant proteolytic activity, whereas
the pH achieved with omeprazole 30
mg/day is high enough largely to abolish
peptic activity [49]. This may partly
explain the superiority of PPIs over
H2RAs in the treatment of acid-related
diseases because of the successful elimi-
nation of an additional aggressive factor
the peptic activity.
It is known that lansoprazole has a
better bioavailability than omeprazole
after oral administration as shown in dou-
ble-blind, randomized cross-over studies
[50, 51]. After the first dose, the bioavail-
ability of lansoprazole is greater than 85
percent and remains constant after repeat-
ed dosing [51]. This has been confirmed in
our recent study in healthy volunteers in
whom once daily lansoprazole 30 mg was
used on four days, and the maximum anti-
secretory effect was obtained six hours
after the first dose and was consistent with
repeated dosing [52], whereas the
bioavailability of omeprazole is only 35
percent after the first dose and rises to
about 60 percent after repeated dosing
[53]. The plasma half-life of lansoprazole
also is longer and the tmax is significantly
shorter and, hence, lansoprazole has a
faster onset ofaction than omeprazole [51,
54]. The pharmacokinetic differences
between these two PPIs may explain the
different effect of these two drugs on
inhibiting gastric acid secretion and, thus,
improvement of symptoms and possibly
healing of GERD. In a placebo-controlled
study, both lansoprazole 30 mg/day and
omeprazole 20 mg/day were significantly
better than placebo in increasing 24-hr
intragastric pH and decreasing basal and
pentagastrin-stimulated acid secretion
[50]. However, the effect of lansoprazole
on intragastric pH was consistently better
than omeprazole. Lansoprazole had a sig-
nificantly longer effect than omeprazole
on maintaining the intragastric pH above 3
over the 24-hr period [50]. In a compara-
tive study, Dammann et al. have shown
that, when compared with placebo, lanso-
prazole 30 mg/day decreased meal-stimu-
lated acid secretion over a 24-hr period on
the first day by 45.1 percent, followed by
omeprazole 40 mg/day by 41.7 percent,
lansoprazole 15 mg/day by 34.6 percent
and omeprazole 20 mg/day by 15.6 per-
cent [51]. There is a dose-dependent effect
for lansoprazole and omeprazole on the
suppression of intragastric acidity with a
potency order of lansoprazole 60 mg >
lansoprazole 30 mg = omeprazole 40 mg >
lansoprazole 15 mg = omeprazole 20 mg
[51, 54, 55].
CLINICALTRIALS IN THETREAT-
MENT OF GERD
The aims of medical treatment of
GERD are to relieve the symptoms, to heal
established esophageal mucosal damage
and to prevent the development ofcompli-
cations. In order to achieve these goals,
treatment needs eitherto prevent the reflux
of acidic gastric contents into the esopha-
gus or to reduce the injurious action of
acid to alevel that will allow healing ofthe
esophageal mucosa to occur. Currently,
there are no effective agents that can
restore fully the motor defects that lead to
pathological acid exposure inpatients with
GERD. Therefore, suppression of acid
secretion remains the mainstay of medical
treatment for patients with GERD.
H2RAs
The effect ofH2RAs on the healing of
erosive esophagitis has proved disappoint-
ing [11, 56]. Complete healing of severe
esophagitis is rare although patients gener-
ally benefit from symptomatic improve-
ment. It is known that H2RAs have certain
pharmacokinetic and pharmacodynamic
characteristics that limit the effect, such as
short duration of effect, incomplete sup-
pression ofacid secretion, particularly that
stimulated by meals [31-33], the develop-
ment of tolerance [41] and acid rebound
[57].
In a meta-analysis, We have show that
early studies with standard dose of raniti-
dine 150 mg twice daily healed 38.6 per-
cent of the patients with grades II to IV at
four weeks and 54.3 percent ateight weeks186 Huang and Hunt:pH, healing and symptoms in patients with GERD
[11, 58-71]. Complete symptom relief is
seen in 42.4 percent ofthe patients at four
weeks and 50.6 percent at eightweeks [11,
59, 61, 63, 69, 72]. In a placebo-controlled
study, Robinson et al. showed that famoti-
dine 20 mg twice daily improved symp-
toms in 69.9 percent of the patients with-
out erosive esophagitis at two weeks and
81.8 percent at six weeks, which was sig-
nificantly better than famotidine 40 mg
nocte. and placebo [73]. The modest effect
on erosive esophagitis seen with standard
doses of H2RAs may result from its rela-
tively weak effect on the suppression of
gastric acid secretion as discussed above.
In order to increase the effect ofheal-
ing esophagitis and relief of symptoms,
higher doses of H2RAs and or more fre-
quent dosing have been used and show
better results than those achieved with
standard doses [74-77]. It is known that
higher doses or more frequent dosing with
H2RAs is associated with an increased
suppression of gastric acid secretion over
24 hours, including meal-stimulated inte-
grated acid secretion [75, 78]. This corre-
lates with higher healing rates in patients
with esophagitis and faster reliefof symp-
toms than with standard doses of H2RAs
in head-to-head comparison studies [58,
72, 74, 77]. The results of Johnson et al.
show that, in patients with grade II to III
esophagitis, treatment with ranitidine 300
mg four times a day healed 63 percent of
the patients after four weeks and 75 per-
cent after eight weeks, whereas in patients
receiving ranitidine 150 mg twice daily,
the healing rates were 29 percent at four
weeks and 54 percent at eight weeks,
respectively. The differences were highly
significant (both p < .01) [58]. Signifi-
cantly more patients had complete symp-
tomatic relief on treatment with the higher
dose of ranitidine at four and eight weeks
(67 percent vs. 46 percent and 84 percent
vs. 64 percent, both p < .05). In several
other studies involving ranitidine 150 mg
four times a day [72, 79-81], an approved
healing dose of ranitidine for esophagitis
in the USA, the healing rates ofesophagi-
tis ranged from 37 to 49 percent at four
weeks and 62 to 69 percent at eight weeks,
respectively. Therefore, with higher doses
of H2RAs, faster healing of esophagitis
and more rapid relief of reflux symptoms
can be achieved.
Studies comparing H2RAs with PPIs
As shown above, PPIs have a greater
inhibitory effect on gastric acid secretion
than H2RAs. This is reflected in the results
of numerous clinical trials showing that
significantly more patients with esophagi-
tis are healed with PPIs than H2RAs. In
five head-to-head comparative studies car-
ried out in the USA and Europe [64, 82-
85], lansoprazole 30 mg daily was consis-
tently and significantly better than a stan-
dard dose ofranitidine 150 mg twice daily
in healing esophagitis and relief of reflux
symptoms. In a randomized, multicenter,
comparative study, 229 patients with
grades I to III esophagitis were random-
ized to receive lansoprazole 30 mg daily,
60 mg daily or ranitidine 150 mg twice
daily for up to eight weeks [64]. At four
weeks, by intention-to-treat analysis, heal-
ing was achieved in 84 percent and 72 per-
cent of the patients receiving lansoprazole
30 mg and 60 mg, respectively, whereas
only 39 percent ofthepatients were healed
with ranitidine 150 mg twice daily. There
was a significant difference between the
two doses oflansoprazole and ranitidine in
the healing rates (p < .01). After eight
weeks, the corresponding figures were 92
percent, 91 percent and 53 percent, respec-
tively, with significantly more patients
healed with lansoprazole than with raniti-
dine (p < .01). These differences were not
influenced by smoking, drinking, patient
age or sex and were seen across all grades
ofesophagitis [64]. Heartburn was signifi-
cantly reduced in more patients treated
with lansoprazole than with ranitidine at
the four- and eight-week assessments
either by physicians or by patients.
Furthermore, patients receiving lansopra-
zole took less antacids on fewer days than
those treated with ranitidine (p < .01) [64].
In a more recent study, Sontag et al.
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study that the superiority of lansoprazole
over ranitidine is also seen in healing ero-
sive esophagitis in patients with Barrett's
esophagus [82]. A total of 105 patients
were randomly allocated to lansoprazole
30 mg daily and ranitidine 150 mg twice
daily for eight weeks. A large and signifi-
cant difference in healing rates was found
between patients treated with lansoprazole
and ranitidine being 32 percent at 2 weeks,
37 percent at four weeks and 33 percent at
eight weeks, respectively (all p < .001)
[82]. Significantly fewer patients in the
lansoprazole group had heartburn during
treatment than those in the raniditine
group [82].
Similar results have also been report-
ed in early studies comparing omeprazole
with standard dose ofH2RAs [86, 87]. In a
double-blind, multi-center, comparative
study, Sandmark compared the effect of
omeprazole 20 mg daily with ranitidine
150 mg twice daily on endoscopic healing
of esophagitis and relief of symptoms in
144 patients with grades II to IV GERD
[61]. The healing rates were 67 percent
and 31 percent at four weeks in the
omeprazole and ranitidine groups by per-
protocol analysis, and 85 percent and 50
percent at eight weeks, respectively. Both
differences were highly significant (p <
.0001) [61]. More interestingly, 51 percent
patients in the omeprazole group experi-
enced substantial symptom improvement
at the end of the first week of treatment,
compared with only 27 percent of those
receiving ranitidine (p = .009). Adverse
events were comparable between these
two groups [61]. A recent article combin-
ing two individual comparative studies
with a total of 550 patients showed that
omeprazole 20 mg daily is significantly
more effective than standard-dose H2RAs
in healing grade I to IV esophagitis and
relieving reflux symptoms [88]. Moreover,
the advantage of omeprazole over H2RAs
was not influenced by patient age.
Therefore, in comparison with standard
doses of H2RAs, omeprazole has proved
consistently more effective in providing
faster relief of reflux symptoms and rapid
healing ofesophagitis.
High doses or frequent dosing regi-
mens ofH2RAs have been studied in order
to increase the effect ofH2RAs on healing
esophagitis. Ranitidine 150 mg four times
a day and 300 mg four times a day or 300
mg twice daily were used in three random-
ized, comparative studies showing similar
results in healing esophagitis between
these dose regimens [79-81]. Ranitidine
150 mg four times a day is as effective as
ranitidine 300 mg four times a day in heal-
ing esophagitis of grades II to IV.
Although significantly more patients were
healed with higher doses of H2RAs than
with the standard doses, about 30 percent
of patients did not respond to these dose
regimens after eight weeks of treatment.
Furthermore, these doses were not effec-
tive in patients with severe esophagitis
with an average of 50 percent unhealed at
eight weeks, and treatment is not cost-
effective when compared with lansopra-
zole 30 mg daily or omeprazole 20 mg
daily [89, 90].
In numerous clinical trials, PPIs have
proved more effective in healing erosive
esophagitis than H2RAs with either stan-
dard or higher doses in patients with
esophagitis and especially in those with
severe disease orrefractory to H2RAs. In a
double-blind, randomized, multi-center
study comparing the effect oflansoprazole
30 mg daily and ranitidine 300 mg twice
daily on healing ofpatients with moderate
and severe esophagitis, four and eight
weeks of treatment with lansoprazole
healed 79.4 percent and 91.2 percent
patients by intention-to-treat analysis,
respectively, while the corresponding fig-
ures for patients receiving ranitidine were
41.5 percent and 66.2 percent, respective-
ly. There was a significant difference in
healing rates between the two groups at
both 4 and 8 weeks (p < .001) [91].
Symptom improvement as evaluated on a
visual analog scale (VAS) was significant-
ly better in patients treated with lansopra-
zole as compared to those on ranitidine.188 Huang and Hunt:pH, healing and symptoms in patients with GERD
TheVAS decreased from 65.1 mm at entry
to 13.5 mm at 4 weeks and 11.3 mm at 8
weeks in the lansoprazole group. In the
ranitidine group, the corresponding figures
were 63.5, 22.8 and 18.5 mm, respective-
ly. Adverse events were comparable in
both groups [91]. Therefore, even with a
higher dose of H2RAs, PPIs proved to be
consistently and significantly better for
healing all grades of esophagitis and for
the relief ofreflux symptoms.
In another randomized, double-blind,
multicenter study Bate et al. compared the
differences between omeprazole 20 mg
daily and cimetidine 400 mg four times a
day in healing esophagitis and relief of
symptoms in patients with grade I to IV
esophagitis [92]. After four weeks oftreat-
ment, 56 percent of the patients in the
omeprazole group were healed, whereas
complete healing occurred in only 26 per-
cent ofthepatients treated with cimetidine.
The corresponding figures at eight weeks
were 71 percent and 35 percent in patients
treated with omeprazole and cimetidine,
respectively. The difference was signifi-
cant at both four and eight weeks between
the two groups (p < .001) [92]. Moreover,
healing was consistent at four and eight
weeks among all grades of esophagitis in
patients treated with omeprazole, while in
the cimetidine group there was a signifi-
cantly inverse correlation between endo-
scopic grades at entry and the healing rates
at four and eight weeks (r = -0.98 and -
0.99, respectively), and no patients with
grade IV esophagitis at entry were healed
after four and eight weeks. Increasing
treatment duration from four weeks to
eight weeks only healed 9 percent more
patients with cimetidine, while the thera-
peutic gain was 15 percent with omepra-
zole [92]. Furthermore, significantly more
patients became asymptomatic in the
omeprazole group than in the cimetidine
group atboth four andeight weeks (46per-
cent vs. 22 percent and 66 percent vs. 41
percent, both p < .001).
Studies comparing lansoprazole with
omeprazole
Four head-to-head studies have com-
pared the effects of lansoprazole and
omeprazole in the treatment of esophagi-
tis. The recursive search found another
abstract meeting the inclusion criteria, and
this has been included for analysis with a
total of 1013 patients. Lansoprazole 30 mg
daily was used in all five studies.
Omeprazole 20 mg daily was used in four
studies and 40 mg daily in one study. The
pooled results show that healing rates at
four weeks are 73.7 percent for lansopra-
zole and 71.5 percent for omeprazole,
respectively, with an odds ratio of 1.12 (95
percent CI: 0.92 - 1.37; Mantel-Haenszel
2 x 2 tables, d.f. = n - 1). At eight weeks,
the pooled healing rates are 83 percent for
lansoprazole and 81.7 percent for omepra-
zole, respectively, with an odds ratio of
1.09 (95 percent CI: 0.86 - 1.4).
There are four studies in the literature
with data for evaluation of symptoms.
Three have shown that lansoprazole is
superior to omeprazole in the relief of
symptoms as assessed by patients and
investigators [93-95]. In a large U.S.
multi-center, randomized, double-blind
and placebo-controlledstudy involving
1284 patients with grade II to IV esophagi-
tis, Castell et al. compared two different
doses of lansoprazole (15 mg and 30 mg
daily) with omeprazole (20 mg daily) in
healing esophagitis (above grade II) and
relief of reflux symptoms [94]. By inten-
tion-to-treat analysis, both lansoprazole 30
mg daily and omeprazole 20 mg daily
were significantly more effective than lan-
soprazole 15 mg daily inhealing esophagi-
tis at both four and eight weeks. The heal-
ing rates were almost identical between
lansoprazole 30 mg daily and omeprazole
20 mg daily (79.6 percent vs. 79.6 percent
at four weeks and 87.2 percent vs. 87 per-
cent at eight weeks, respectively).
However, there was a significant differ-
ence in symptom reliefbetween these twoHuang and Hunt:pH, healing and symptoms in patients with GERD 189
groups. After the first day of treatment,
significantly fewer patients in the lanso-
prazole group experienced daytime and
nighttime heartburn than patients receiv-
ing omeprazole (38 percent vs. 48 percent,
p < .05). This advantage was maintained
throughout the duration of the eight-week
treatment with a significant reduction in
antacids use in patients treated with lanso-
prazole. The incidence of adverse events
was comparable between the two groups
[94].
Another large study consisting of 604
patients from the U.K. showed similar
results [95]. After three days of treatment,
significantly greater symptom relief of
daytime heartburn was achieved in
patients treated with lansoprazole 30 mg
daily (median change in VAS: -20.2 mm)
when compared to those receiving
omeprazole 20 mg daily (median change
in VAS: -15.3 mm) as indicated by a
greater change in VAS score from baseline
[95]. Similar results also were reported in
a Scandinavian multi-center, randomized
trial in which significantly more patients
treated with lansoprazole 30 mg daily
experienced a greater improvement in
heartburn than those receiving omeprazole
20 mg daily [93].
Mulder et al. reported a Dutch multi-
center study showing that there was no
significant difference in terms of healing
of esophagitis and relief of symptoms at
both four and eight weeks between
patients treated with lansoprazole or
omeprazole [96]. Since omeprazole 40 mg
daily was used to compare with lansopra-
zole 30 mg daily in this study, it is difficult
to make a comparison on a dose-by-dose
basis.
As discussed earlier in this paper,
reflux symptoms are significantly associ-
ated with esophageal acid exposure time
(pH < 4). Since lansoprazole 30 mg daily
has a rapid onset and longer-lasting sup-
pression ofacid secretion than omeprazole
20 mg daily [50, 51, 54, 55], it is under-
standable why lansoprazole is superior to
omeprazole in relieving reflux symptoms
in patients with GERD.
SUMMARY AND CONCLUSIONS
Although GERD is recognized as a
motility disorder, gastric acid together
with pepsin have been considered as key
factors in initiating and perpetuating the
mucosal damage to the esophageal
mucosa and the development ofsymptoms
in patients with esophagitis. There is a
dynamic relationship between the degree
and duration of esophageal acid exposure
and healing ofesophagitis. The longer the
intragastric pH is above 4, the more
patients will be healed at any arbitrary
time-point. Treatments to relieve reflux
symptoms and heal esophagitis with
H2RAs have been surprisingly unsuccess-
ful. This correlates with the ineffectiveness
of H2RAs in suppressing gastric acid
secretion. High-dose H2RAs are more
effective than standard doses in reducing
acid secretion, but the advantage is modest
in improving healing rates in esophagitis,
and they are ineffective in patients with
severe esophagitis; moreover, there is a
higher cost. PPIs are very effective acid-
suppressing agents under all conditions
and are effective in healing all grades of
esophagitis. In comparison with other
medical treatments, PPIs produce the
fastest healing and relief of reflux symp-
toms. The advantage of PPIs over H2RAs
is associated with the greater degree,
longer duration and more complete inhibi-
tion of acid secretion, which provides a
longer effect in maintaining intragastric
pH above 4. Lansoprazole has a better
bioavailability and a longer effect on sup-
pressing acid secretion than omeprazole
after oral administration. In clinical trials,
significantly more patients have reflux
symptom relief after treatment with lanso-
prazole than with omeprazole, although
there is not significant difference in heal-
ing esophagitis between these two PPIs.
This suggests that, overall, greater acid
suppression may result in greater improve-
ment ofquality oflife in patients with ero-
sive esophagitis [97].190 Huang and Hunt:pH, healing andsymptoms in patients with GERD
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